
Fate Therapeutics (FATE) Stock Forecast & Price Target
Fate Therapeutics (FATE) Analyst Ratings
Bulls say
Fate Therapeutics Inc. has demonstrated promising early results for its FT819 cell therapy in patients with lupus, showcasing significant improvements in clinical measures such as SLEDAI-2K, including reductions from baseline scores and instances of drug-free remission beyond one year. The positive data presented at both the EULAR and ACR meetings indicates that FT819 could offer a durable and effective treatment option for heavily pretreated patients, emphasizing its potential as an allogeneic CAR-T therapy in the lupus market. With encouraging clinical outcomes and a robust development pipeline focused on immunotherapies, Fate Therapeutics's stock outlook remains favorable as it continues to further its innovative therapeutic advancements.
Bears say
Fate Therapeutics Inc faces significant risks that contribute to a negative outlook, including the uncertainty surrounding the clinical efficacy of its lead product, FT819, particularly in comparison to existing CAR-T therapies. The data from early trials suggest only transient effects with limited patient follow-up, making it difficult to assess the long-term clinical benefits of FT819. Additionally, potential partnership challenges, regulatory hurdles, and medium-term dilution risks further complicate the company’s financial stability and future growth prospects.
This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Fate Therapeutics (FATE) Analyst Forecast & Price Prediction
Start investing in Fate Therapeutics (FATE)
Order type
Buy in
Order amount
Est. shares
0 shares